Wedbush Has Optimistic Outlook of FENC FY2025 Earnings

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Equities researchers at Wedbush upped their FY2025 earnings per share estimates for shares of Fennec Pharmaceuticals in a research report issued on Monday, March 10th. Wedbush analyst D. Nierengarten now forecasts that the company will earn $0.55 per share for the year, up from their prior estimate of $0.46. Wedbush currently has a “Outperform” rating and a $13.00 target price on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is ($0.11) per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ FY2027 earnings at $2.84 EPS.

Several other research analysts have also commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Fennec Pharmaceuticals in a research report on Tuesday. Stephens raised Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th.

Fennec Pharmaceuticals Stock Performance

Shares of NASDAQ FENC opened at $6.40 on Wednesday. Fennec Pharmaceuticals has a fifty-two week low of $3.96 and a fifty-two week high of $11.49. The firm has a market capitalization of $176.40 million, a PE ratio of -63.99 and a beta of 0.36. The stock’s 50-day simple moving average is $6.39 and its 200-day simple moving average is $5.62.

Institutional Investors Weigh In On Fennec Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Intech Investment Management LLC purchased a new stake in shares of Fennec Pharmaceuticals in the fourth quarter worth about $69,000. Franklin Resources Inc. raised its stake in Fennec Pharmaceuticals by 18.7% during the third quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock valued at $74,000 after buying an additional 2,330 shares in the last quarter. Wells Fargo & Company MN raised its stake in Fennec Pharmaceuticals by 31.6% during the fourth quarter. Wells Fargo & Company MN now owns 13,152 shares of the company’s stock valued at $83,000 after buying an additional 3,155 shares in the last quarter. Pinnacle Wealth Planning Services Inc. acquired a new stake in shares of Fennec Pharmaceuticals during the 4th quarter worth approximately $97,000. Finally, MetLife Investment Management LLC acquired a new stake in shares of Fennec Pharmaceuticals during the 4th quarter worth approximately $99,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Insider Activity at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, Director Rosty Raykov sold 10,000 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $6.79, for a total transaction of $67,900.00. Following the completion of the sale, the director now owns 68,725 shares of the company’s stock, valued at approximately $466,642.75. The trade was a 12.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders sold 31,186 shares of company stock worth $203,389. 10.98% of the stock is currently owned by insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.